Company

Our Journey

From a specialized ion channel laboratory in 2018 to a global biotech company in 2026 — the RudaCure story.

2026

Series B & Global Expansion

RCI001 FDA Phase 2 interim results. RuCIA platform expansion into rare sensory diseases. Pre-IPO funding and Japan/Europe licensing deals.

Q1Pre-IPO funding round in progress
Q2RCI001 FDA Phase 2 interim results expected
2025

Clinical & IPO Milestones

RCI001 FDA Phase 2 IND approval. IPO underwriter selection. Incheon Outstanding Company & Hi-Seoul certification.

Jan2025 New Year ceremony & Outstanding/Model Employee awards
FebPOSTECH Prof. Kwon TRPV1 structural analysis seminar
MarRCI001 Phase 2 advisory meeting (13 ophthalmologists). Bio-Europe Spring & French Veterinary Pharma meeting
AprESG activities — Anyang Stream plogging & blood donation campaign
MayAgri-Food Venture Program selected (veterinary gene therapy). Bio-Korea booth. Syntekabio Collabo R&D
JunBIO-USA global partnering (Santen, Thea). European Dry Eye Society — RCI001 presentation
Jul7th anniversary celebration & 5-year service awards. H1 performance review workshop
AugRCI001 FDA Phase 2 IND approval. DT&CRO research MOU signed. Japan patent registered
OctHi-Seoul Enterprise certification. Pain Therapeutics Summit attendance
NovIncheon Outstanding Company award. SfN next-gen pain therapeutics presentation
DecIPO underwriter selection. 1-ton cat food donation to stray cat shelter (CSR)
2024

Clinical Validation & Unicorn Selection

RCI001 domestic Phase 1 clinical trial. Baby Unicorn designation. Scale-up TIPS KRW 1.2B.

Jan2024 New Year ceremony
MarRCI001 domestic Phase 1 clinical trial approval. Visit to French Veterinary Pharma (RCI001AH co-development)
AprIBK Innovation Hub Europe accelerator program
MayESG management initiatives launched. Bio-Korea BioHealth pavilion
JunSelected as 'Baby Unicorn' by Ministry of SMEs. BIO-USA 2024 attendance
OctScale-up TIPS selected (KRW 1.2B over 3 years). RCI001 efficacy in Sjögren's syndrome model
DecCore Innovation Korea 2024 Grand Prize. Syntekabio anticancer drug discovery contract
2023

Strategic Partnerships & Global Reach

Two Hanlim Pharma tech transfers. Veterinary pharma initiative. ACR conference presentation.

JanHanlim Pharma corneal treatment RCI001U tech transfer. Rac1 inhibitor KRW 7B L/O deal
FebNovel pain peptide patent filed
MarVeterinary pharma partnership with Onheal/OnhealPet. Bio-EU partnering
AprMinistry of Employment Strong SME designation. Startup Leap Package selection
MayDarae Strategic Center tech consulting agreement
JunASCO clinical oncology delegation
SepEye drop formulation patent filed
OctSeoul tech commercialization program. Prof. Kim RCI001 long-term safety study. Singapore Global Innovation Roadshow
NovACR — TRPV1 osteoarthritis therapeutic presentation. KICDC/Defy Pitch Prize. Bio-Europe 2023
DecHallym Univ. Hospital-IonCell CAR-T/ADC co-research MOU
2022

Investment & Global Recognition

Series A KRW 6B raised. RESI 3rd place. US clinical preparations.

FebJPM conference meetings. KIC Washington bio startup challenge
AprShinhan Square Bridge Incheon. INNOBIZ certification. KIC Washington partnership
MaySeries A KRW 6B investment raised. ARVO conference
JunBIO-USA Korean pavilion. RCI001 dry eye innovation drug spotlight
AugUKC 2022 IR Competition SBA Award. Seoul Gasan office relocation. Gachon Univ. national drug project
SepRESI Innovator's Pitch Challenge — 3rd place
OctTRPV1 patent filed in Japan/China
NovTalent-Nurturing SME designation
DecFamily-Friendly certification & Youth-Friendly Strong SME
2021

Tech Transfer & US Subsidiary

Hanlim Pharma KRW 15B tech transfer. RudaCure U.S.A. established. Multiple government grants.

JanSunBio preclinical CRO annual contract. TRPV1 US patent filed
MarUS clinical CRO (Ora) contract. Relocated to Incheon Startup Park
AprHanlim Pharma KRW 15B RCI001 tech transfer. Prof. Kim Nature sister journal paper. Bio-Medical Tech Development project
MayBIG3 commercialization project. Doctor-startup co-research program
JunEVP Kim selected as TOFS committee member. BioKorea 2021
AugRudaCure U.S.A. Inc. established. MSIT infectious disease platform project. Bio-iCore program
DecDomestic TRPV1 patent secured. Prof. Kim — KOES Academic Award & Taejun Best Paper Award
2020

Pipeline Foundation

RCI001 clinical trial groundwork. BIG3 Innovation Growth selection. Incheon Startup Park.

FebPain & ophthalmic drug research fully launched
JunR&D Rediscovery Project selected. BIG3 Innovation Startup Package
JulRCI001 clinical trial foundation established. Incheon Startup Park entry (Boost Startup Journey)
AugGlobal IP Support Program selected
DecSunBio MucoPEG US clinical contract. Incheon R&D consulting program
2019

Early Research & Tech Transfer

Gil Hospital ophthalmic patent transfer. Asia Pain Symposium hosted.

DecGil Hospital geriatric eye disease patent transfer. Asia Pain Symposium in Songdo. Bundang CHA Hospital spine regeneration co-development
2018

Foundation

Founded by Dr. Yong-ho Kim (Gachon University). Ion channel-targeted therapeutics for pain and sensory diseases.

Leadership

Our Team

Dr. Yong-ho Kim

Founder & CEO

Gachon University professor specializing in ion channel pharmacology and pain research.

Seung-hoon Kim

Vice President

CMC operations, AI platform development, and corporate strategy.